Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christina N Carrigan

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Analytical Biochemistry|May 24, 2005
The engineering of membrane-permeable peptidesChristina N Carrigan, Barbara Imperiali
Journal of the American Chemical Society|September 17, 2004
Zinc is an essential cofactor for type I isopentenyl diphosphate:dimethylallyl diphosphate isomeraseChristina N Carrigan, C Dale Poulter
Tetrahedron|June 23, 2009
Caged O-phosphorothioyl amino acids as building blocks for Fmoc-based solid phase peptide synthesisAndreas Aemissegger, Christina N Carrigan, Barbara Imperiali
Current Medicinal Chemistry|August 17, 2005
Inhibitor of the glutamate vesicular transporter (VGLUT)Charles M Thompson, Erin Davis, Christina N Carrigan, et al.
Journal of Medicinal Chemistry|May 17, 2002
Synthesis and in vitro pharmacology of substituted quinoline-2,4-dicarboxylic acids as inhibitors of vesicular glutamate transportChristina N Carrigan, Richard D Bartlett, C Sean Esslinger, et al.
Bioorganic & Medicinal Chemistry Letters|January 16, 2014
The development of benzo- and naphtho-fused quinoline-2,4-dicarboxylic acids as vesicular glutamate transporter (VGLUT) inhibitors reveals a possible role for neuroactive steroidsChristina N Carrigan, Sarjubhai A Patel, Holly D Cox, et al.
Mabs|February 5, 2014
Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft modelsKathleen R Whiteman, Holly A Johnson, Michele F Mayo, et al.
Blood|September 5, 2013
A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignanciesJutta Deckert, Peter U Park, Sharon Chicklas, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Analytical Biochemistry|May 24, 2005
The engineering of membrane-permeable peptidesChristina N Carrigan, Barbara Imperiali
Journal of the American Chemical Society|September 17, 2004
Zinc is an essential cofactor for type I isopentenyl diphosphate:dimethylallyl diphosphate isomeraseChristina N Carrigan, C Dale Poulter
Tetrahedron|June 23, 2009
Caged O-phosphorothioyl amino acids as building blocks for Fmoc-based solid phase peptide synthesisAndreas Aemissegger, Christina N Carrigan, Barbara Imperiali
Current Medicinal Chemistry|August 17, 2005
Inhibitor of the glutamate vesicular transporter (VGLUT)Charles M Thompson, Erin Davis, Christina N Carrigan, et al.
Journal of Medicinal Chemistry|May 17, 2002
Synthesis and in vitro pharmacology of substituted quinoline-2,4-dicarboxylic acids as inhibitors of vesicular glutamate transportChristina N Carrigan, Richard D Bartlett, C Sean Esslinger, et al.
Bioorganic & Medicinal Chemistry Letters|January 16, 2014
The development of benzo- and naphtho-fused quinoline-2,4-dicarboxylic acids as vesicular glutamate transporter (VGLUT) inhibitors reveals a possible role for neuroactive steroidsChristina N Carrigan, Sarjubhai A Patel, Holly D Cox, et al.
Mabs|February 5, 2014
Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft modelsKathleen R Whiteman, Holly A Johnson, Michele F Mayo, et al.
Blood|September 5, 2013
A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignanciesJutta Deckert, Peter U Park, Sharon Chicklas, et al.
Pageof 1